
    
      Participants will receive one dose of SP059 (at Visit 1) as a booster vaccination at an age
      from 4 to 6 years. They will be assessed for immunogenicity at baseline (pre-vaccination) and
      at 4-6 weeks post- vaccination.

      Safety data including serious adverse events (SAEs) after vaccination will be collected
      during the study period.
    
  